Middle East healthcare industry continues to attract international investors – ZAWYA

Middle East healthcare industry continues to attract international investors – ZAWYA

Marubeni acquires a minority stake in Lunatus, a Middle East healthcare turnkey solutions provider
The fast-growing Middle East healthcare industry, driven by the increase of healthcare related expenditures from both the public and private sectors, fuels the interest of international companies looking to invest in this growing sector in Middle East in general and the UAE in particular.
Marubeni Corporation (hereinafter, “Marubeni”) and Lunatus Marketing & Consulting FZCO (hereinafter, “Lunatus”) have announced that Marubeni invested and acquired shares in Dubai Based Lunatus.
Lunatus, one of the largest and fastest growing pharmaceutical companies in the MENA region, is a market-leading turnkey solutions provider that handles regulatory, marketing, sales, distribution, and supply chain management for international pharmaceutical & medical device companies. Marubeni, a leading Japanese integrated trading and investment business conglomerate, has its healthcare & medical industry business network in China(*1) , ASEAN(*2) etc. with the intention to expand the network globally, Marubeni identifies the growth potential in pharmaceutical-related business and medical service businesses in Middle East.
Through the broad regional Lunatus network , Marubeni will bridge the Japan-Middle East markets and will bring Japanese high-quality pharmaceuticals and medical devices to Middle East to accommodate the increasing demand in the region. Moreover, by leveraging their joint expertise, Marubeni and Lunatus intend to explore expanding the business across the other emerging markets including ASEAN and Africa.
Mr. Eisuke Kamide, General Manager of Marubeni’s Healthcare & Medical Business Department, commented: “We are proud to form a strategic alliance partnership with Lunatus, and will continue exploring opportunities in the Middle East pharmaceutical market. Marubeni is focused on the MENA market which has a large growth potential, and this transaction will enable us to expand our pharmaceutical and medical device business network from China to the Middle East and Africa. Through these efforts, we would like to reduce the healthcare disparity globally and regionally, bringing value to all patients, families and stakeholders.
Dr. Lina Kouatly, Founder and Chief Executive Officer of Lunatus commented: “Over the last 19 years, we have built one of the largest regional pharmaceutical companies spanning the GCC and Levant regions. We are thrilled to partner with Marubeni in further consolidating and expanding our footprint as we explore unique growth opportunities regionally and into the Asian markets. This transaction presents a unique strategic opportunity to partner alongside Marubeni, a global conglomerate, in further growing the Lunatus brand.”
(*1) Marubeni formed joint venture called “Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd.” with Chinese pharmaceutical company “Shanghai Fosun Pharmaceutical (group)”.
(https://www.marubeni.com/en/news/2017/release/00020.html)
(*2) One of the examples of medical service businesses are the one which Marubeni invested in Indonesia’s leading hospital operator “PT Slioam International Hospitals Tbk.”
(https://www.marubeni.com/en/news/2020/release/2020022502E.pdf)

© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

source


Leave a Reply

Your email address will not be published.